Keith T. Flaherty, MD

Dr. Flaherty on the Significance of the NCI-MATCH Precision Medicine Trial

December 5th 2020

Keith T. Flaherty, MD, discusses the significance of the NCI-MATCH study.

Dr. Flaherty on Second-Line Therapy for BRAF-Mutant Melanoma

September 24th 2019

Keith T. Flaherty, MD, discusses treatment beyond frontline therapy for patients with BRAF-mutant relapsed/refractory melanoma.

Dr. Flaherty on the Rationale to Explore Triplet Therapy in BRAF V600E-Mutant Melanoma

August 1st 2019

Keith T. Flaherty, MD, director, Henri and Belinda Termeer Center for Targeted Therapy and director of clinical research, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses the rationale to explore triplet therapy in BRAF V600-mutant melanoma.

Dr. Flaherty on the COLUMBUS Trial Updates in BRAF-Mutant Melanoma

July 24th 2019

Keith T. Flaherty, MD, discusses an update on overall survival in COLUMBUS, a randomized phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

Dr. Flaherty Discusses BRAF Inhibitors in Melanoma

October 11th 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses BRAF inhibitors for the treatment of patients with melanoma.

Dr. Flaherty on the Tolerability of Encorafenib/Binimetinib in Melanoma

August 31st 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the tolerability of the combination of encorafenib (Braftovi) and binimetinib (Mektovi) in patients with melanoma.

Dr. Flaherty Discusses the COLUMBUS Trial in Melanoma

June 12th 2018

Keith T. Flaherty, MD, director, Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, professor of medicine, Harvard Medical School, discusses the COLUMBUS trial in patients with BRAF-mutant melanoma.

Dr. Keith Flaherty Discusses Long-Term Data from the COLUMBUS Trial

November 10th 2016

Keith T. Flaherty, MD, director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital and professor of Medicine, Harvard Medical School, discusses the results from the COLUMBUS trial, testing encorafenib plus binimetinib compared to vemurafenib or encorafenib as single agents.

Dr. Flaherty on Resistance in BRAF-Mutant Melanoma

October 11th 2016

Keith T. Flaherty, MD, director of Developmental Therapeutics at the Cancer Center of Massachusetts General Hospital, discusses resistance that develops in patients with BRAF-mutant melanoma.

Dr. Keith T. Flaherty on the NEMO Trial in NRAS-Mutant Melanoma

August 23rd 2016

Dr. Keith T. Flaherty on 3-Year Follow-up of COMBI-d in Metastatic Melanoma

August 2nd 2016